Neurocrine Biosciences Director Exercises Options and Sells Shares via 10b5-1 Plan

Insider Transaction Overview

On November 3, 2026, George J. Morrow, a Director at Neurocrine Biosciences Inc ($NBIX), reported transactions spanning October 30, November 2, and November 3, 2026. The filings disclose the exercise of stock options expiring in May 2027 and the concurrent sale of the acquired common stock.

Key Transaction Details:

• Option Exercises (Code M): Exercised non-qualified stock options to purchase an aggregate of 15,000 shares at an exercise price of $53.64 per share ($804,600 total exercise cost).
• Open Market Dispositions (Code S): Sold an aggregate of 15,000 shares across multiple tranches at prices ranging between $144.98 and $168.53, generating gross proceeds of approximately $2,335,982 (weighted average price of ~$155.73).
• Net Share Holding Impact: Following these transactions, the insider's direct common stock position remains unchanged at 10,386 shares, while the derivative position (options granted in 2017) was fully exercised down to 0 options.

Context and Significance:

• Trading Plan: All dispositions were executed under a pre-established Rule 10b5-1 trading plan adopted on May 26, 2026.
• Significance Level: Low. The activity represents a routine exercise of options approaching their expiration (May 2027) with simultaneous market sales through a pre-scheduled trading plan, resulting in zero net change to baseline direct equity holdings.